Navigation Links
PAREXEL Reports First Quarter Fiscal Year 2009 Financial Results

- Year-over-year service revenue growth of 26.4%

- GAAP diluted earnings per share of $0.23

BOSTON, Oct. 27 /PRNewswire-FirstCall/ -- PAREXEL International Corporation (Nasdaq: PRXL) today announced its financial results for the first quarter ended September 30, 2008.

For the three months ended September 30, 2008, PAREXEL's consolidated service revenue increased 26.4% to $263.0 million compared with $208.1 million in the prior year period. The Company reported operating income of $22.0 million, or 8.4% of consolidated service revenue, in the first quarter of Fiscal Year 2009, versus operating income of $16.5 million, or 7.9% of consolidated service revenue, in the comparable quarter of the prior year. Net income for the quarter totaled $13.6 million, or $0.23 per diluted share, compared with net income of $13.9 million, or $0.24 per diluted share, for the quarter ended September 30, 2007. Excluding prior period net tax adjustments of $4.0 million or $0.07 per diluted share, net income and earnings per diluted share in the quarter ended September 30, 2007 were $9.9 million and $0.17, respectively. On an adjusted basis, excluding such tax adjustment, net income was up 37.8% and EPS increased 35.3%.

On a segment basis, consolidated service revenue for the first quarter of Fiscal Year 2009 was $202.8 million in Clinical Research Services (CRS), $30.1 million in PAREXEL Consulting and Medical Communications Services (PCMS), and $30.1 million in Perceptive Informatics, Inc.

Backlog at the end of September was $2.061 billion. The reported backlog included gross new business wins of $347 million, an increase in backlog of $117 million related to the ClinPhone acquisition, cancellations of approximately $83 million, and a negative impact from foreign exchange rates of $116 million. The net book-to-burn ratio (defined as gross new business less cancellations divided by service revenue) was approximately 1.0 in the quarter.

Mr. Josef H. von Rickenbach, PAREXEL's Chairman and Chief Executive Officer stated, "Effective cost controls and a lower tax rate helped us to exceed our earnings per share targets during the first quarter.

On the new business front, after achieving robust new business generation in the fourth quarter, we anticipated a slowdown during the summer months, and then expected an acceleration of activity in September as has been typical in the past. Ultimately, however, sales performance for the quarter turned out to be short of target. We have taken action to regain sales momentum and retain market share, even in this more challenging environment."

Mr. von Rickenbach continued, "With regard to our recent acquisition of ClinPhone, the products and services that have been added to the Company have strengthened our technology offering, and we are receiving positive feedback from clients. Some short-term acquisition-related challenges prevented us from achieving the expected quarterly results in the Perceptive Informatics business segment. However, we are pleased with the most recent progress of the business unit, and look forward to improved performance as we move ahead."

The Company issued forward-looking guidance for the second quarter of Fiscal Year 2009 (ending December 31, 2008), and provided updated guidance for Fiscal Year 2009, using recent exchange rates. The Company's revenue and EPS projections have been revised due to the negative impact from the very substantial strengthening of the U.S. dollar and some headwinds in the marketplace. For the second quarter, the Company anticipates reporting consolidated service revenue in the range of $265 to $275 million and earnings per diluted share in the range of $0.18 to $0.20. For Fiscal Year 2009, consolidated service revenue is expected to be in the range of $1.100 to $1.130 billion using recent exchange rates (previously issued revenue guidance was $1.215 to $1.245 billion). Foreign exchange movements account for 70% of the downward revision in service revenue guidance for Fiscal Year 2009. Earnings per diluted share for Fiscal Year 2009 are projected to be in the range of $1.07 and $1.13 (previously issued diluted earnings per share guidance was $1.09 to $1.17).

In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), the Company uses certain non- GAAP financial measures. The Company believes that presenting the non-GAAP financial measures contained in this press release assists investors and others in gaining a better understanding of its core operating results and future prospects, especially when comparing such results to previous periods or forecasted guidance, because such measures exclude items that are outside of the Company's normal operations and/or, in certain cases, are difficult to forecast accurately for future periods. Management uses non-GAAP financial measures, in addition to the measures prepared in accordance with GAAP, as the basis for measuring the Company's core operating performance and comparing such performance to that of prior periods and to the performance of its competitors for the same reasons stated above. Such measures are also used by management in its financial and operating decision-making. Non-GAAP financial measures are not meant to be considered superior to or a substitute for the Company's results of operations prepared in accordance with GAAP.

A conference call to discuss PAREXEL's first quarter earnings, business, and financial outlook will begin at 10:00 a.m. EDT Tuesday, October 28, 2008 and will be broadcast live over the internet via webcast. The webcast may be accessed in the "Webcasts" portion of the Investor Relations section of the Company's website at Users should follow the instructions provided to assure that the necessary audio applications are downloaded and installed. A replay of this webcast will be archived on the website approximately two hours after the call and will continue to be accessible for approximately one year following the live event. To participate via telephone, dial (612) 288-0337 and ask to join the PAREXEL quarterly conference call.

About the Company

PAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, medical communications and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 71 locations throughout 52 countries around the world, and has over 9,180 employees. For more information about PAREXEL International visit

This release contains "forward-looking" statements regarding future results and events, including, without limitation, statements regarding expected financial results, future growth and customer demand, such as the guidance provided by the Company with respect to the second quarter of Fiscal Year 2009 and Fiscal Year 2009. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward- looking statements. Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," "estimates," "projects," "targets," and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company's actual future results may differ significantly from the results discussed in the forward- looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business, including, but not limited to, the successful business integration and anticipated synergy achievements in connection with the ClinPhone acquisition; the impact on the Company's business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Annual Report on Form 10-K for the fiscal year ended June 30, 2008 as filed with the SEC on August 28, 2008, which "Risk Factors" discussion is incorporated by reference in this press release. The forward-looking statements included in this press release represent the Company's estimates as of the date of this release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.

PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of their respective business and are hereby acknowledged.

CONTACTS: James Winschel, Senior Vice President and Chief Financial


Jill Baker, Vice President of Investor Relations


PAREXEL International Corporation

Consolidated Condensed Statement of Operations

(In thousands, except per share data)


For the three months

ended September 30,

2008 2007

Service revenue $263,046 $208,125

Reimbursement revenue 56,506 43,907

Total revenue 319,552 252,032

Costs and expenses:

Direct costs 171,364 136,062

Reimbursable out-of-pocket expenses 56,506 43,907

Selling, general and administrative 57,725 47,140

Depreciation 9,929 7,496

Amortization 2,035 899

Total costs and expenses 297,559 235,504

Income from operations 21,993 16,528

Other expense (223) (426)

Income before income taxes 21,770 16,102

Provision for income taxes 7,696 2,237 (a)

Effective tax rate 35.4% 13.9% (a)

Minority interest expense (benefit) 455 (20)

Net income $13,619 $13,885

Earnings per common share:

Basic $0.24 $0.25

Diluted $0.23 $0.24

Shares used in computing earnings per

common share:

Basic 56,926 55,242

Diluted 58,164 57,082

Balance Sheet Information Preliminary

Sept 30, June 30, Sept 30,

2008 2008 2007

Billed accounts receivable, net $253,663 $253,256 $205,002

Unbilled accounts receivable, net 204,019 222,560 149,378

Deferred revenue (195,601) (213,126) (173,972)

Net receivables $262,081 $262,690 $180,408

Cash and marketable securities $48,153 $51,918 $50,436

Working capital $82,928 $146,535 $75,958

Total assets $1,111,726 $948,071 $735,660

Short-term borrowings $125,084 $66,474 $55,463

Long-term debt $153,784 $3,465 $253

Stockholders' equity $405,028 $428,091 $343,088

(a) Includes a net tax benefit of $4 million, related in part to a

reduction in German tax rates.

PAREXEL International Corporation

Segment Information

($ in thousands)

Three months ended

September 30,

2008 2007

Clinical Research Services (CRS)

Service revenue $202,823 $159,329

% of total service revenue 77.1% 76.5%

Gross profit $70,921 $55,162

Gross margin % of service revenue 35.0% 34.6%

PAREXEL Consulting & Medical Communications

Services (PCMS)

Service revenue $30,111 $30,520

% of total service revenue 11.4% 14.7%

Gross profit $9,948 $9,581

Gross margin % of service revenue 33.0% 31.4%

Perceptive Informatics, Inc. (PII)

Service revenue $30,112 $18,276

% of total service revenue 11.5% 8.8%

Gross profit $10,813 $7,320

Gross margin % of service revenue 35.9% 40.1%

Total service revenue $263,046 $208,125

Total gross profit $91,682 $72,063

Gross margin % of service revenue 34.9% 34.6%

Revenue by Geography

The Americas $102,331 $79,999

Europe, Middle East & Africa 140,387 112,843

Asia/Pacific 20,328 15,283

Total service revenue $263,046 $208,125

Quarterly Supplemental Financial Data

Total revenue $319,552 $252,032

Investigator fees 45,136 39,093

Gross revenue $364,688 $291,125

DSO 66 57

Capital expenditures 19,163 13,036

SOURCE PAREXEL International Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. PAREXEL International to Present at Robert W. Bairds 2008 Growth Stock Conference
2. PAREXEL International to Present at Bank of America 2008 Smid Cap Conference
3. Sharps Compliance Corp. Reports Net Income More Than Doubles on 26% Increase in Revenue in the First Quarter of Fiscal 2009
4. WellPoint Reports Third Quarter 2008 Results
5. Forest Laboratories, Inc. Reports Fiscal Second Quarter 2009 Earnings per Share of $0.80
6. Schering-Plough Reports Financial Results for Third Quarter of 2008
7. Quest Diagnostics Reports Growth in Revenue and Earnings for Third Quarter 2008
8. Exponent Reports Third Quarter 2008 Results
9. SEAL Indiana Reports More Than Half of Indianapolis Area School Kids Treated by Program Have Moderate or Severe Dental Decay
10. Johnson & Johnson Reports 2008 Third-Quarter Results:
11. Combined Insurance Reports that Voluntary Programs Can Offer Employers a Cost Effective Way to Offer Benefits and Help Retain Employees
Post Your Comments:
(Date:12/1/2015)... ... December 01, 2015 , ... For many X-rays taken ... for accurate interpretation by the radiologist. The marking utensils are so small, however, ... has found a way to alleviate this problem. , He developed the patent-pending ...
(Date:12/1/2015)... ... December 01, 2015 , ... Visage accelerates ... a wholly owned subsidiary of Pro Medicus Ltd. (ASX: PME), has announced they ... Society of North America (RSNA) 2015 annual meeting through December 3 in Chicago, ...
(Date:12/1/2015)... ... December 01, 2015 , ... Next ... selected as a finalist in this year’s Fierce Innovation Awards: Healthcare Edition, an ... was recognized as a finalist in the category of Digital Solutions for its ...
(Date:12/1/2015)... ... ... Lutronic, a leading innovator of aesthetic and medical laser and energy-based technology, announced ... the United States. Clarity is a Superior Dual Wavelength Platform which combines two ... platform that is easy to own and operate. , For over a decade, ...
(Date:12/1/2015)... ... December 01, 2015 , ... PYA’s ... Post-Affiliation Integration ,” addresses a main “pain point” for merging or aligning healthcare ... once a deal is signed. This quick-read guidance suggests that failing to ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... 01, 2015 ... addition of the "2016 Europe ... E. Coli, Enterovirus, Rhinovirus, Rotavirus, Salmonella, ... their offering. --> ... the "2016 Europe Enteric Disease ...
(Date:12/1/2015)... -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing ... that the company will present at the LD Micro Main ... Luxe Sunset Boulevard Hotel in Los Angeles, CA. ... will present on Thursday, December 3, at 9:00 am Pacific ... register at least 10 minutes prior to the start of ...
(Date:12/1/2015)... CytRx Corporation (NASDAQ: CYTR ), a ... announced that it has reached its enrollment target of ... clinical trial of aldoxorubicin in patients with previously treated ... completed in Q1 2016. The Phase 3 trial is a ... Assessment from the FDA at 79 sites in ...
Breaking Medicine Technology: